Corneal Densitometry Changes With Adenoviral SEI

Corneal Densitometry Changes With Adenoviral Keratoconjunctivitis Sub Epithelial Infiltrates

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04267991

Enrollment

Registered

2020-02-13

Start date

2018-04-01

Completion date

2020-04-15

Last updated

2020-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Disease

Keywords

adenoviral, infiltrates, PTK, tacrolimus

Brief summary

Adenoviral Sub epithelial infiltrates (SEI) affect ocular function.They lead to reduced vision, photophobia, glare, halos, and foreign body sensation.

Detailed description

first group of patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.S econd group underwent transepithelial PTK for subepithelial infiltrates. Baseline and post-treatment full ophthalmic examination was done.

Interventions

DRUGTacrolimus ointment

Patients were treated with 0.03 % tacrolimus ointment twice daily for 6 months.

PROCEDUREphototherapeutic keratectomy

Patients underwent transepithelial PTK for subepithelial infiltrates.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Inclusion criteria

* adenoviral SEI

Exclusion criteria

* Other corneal diseases

Design outcomes

Primary

Measure	Time frame	Description
changes of corneal densitometry	6 months	Sub epithelial infiltrates was examined with the densitometry programme of the Pentacam (Fa. Oculus,Weimar, Germany)

Countries

United Arab Emirates

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026